Business
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment designed to transform any causal or frontier Large Language Model (LLM) into a high-performance engine for real-world drug discovery and development tasks.
About this update from Insilico Medicine Cayman Topco
[{"type":"list","items":[{"val":[{"type":"text","content":"New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Advances Insilico's vision of Pharmaceutical Superintelligence (PSI)","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":313,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment designed to transform any causal or frontier Large Language Model (LLM) into a high-performance engine for real-world drug discovery and development tasks.","length":424,"tagName":"p"},{"type":"text","content":"Building on more than a decade of AI research and its own internal pipeline of 27 preclinical candidates, 10+ molecules with IND clearance, and multiple Phase I and Phase IIa clinical trials completed or ongoing, Insilico is now opening its AI training infrastructure to external partners. Science MMAI Gym adapts general-purpose LLMs (such as GPT, Claude, Gemini, Grok, Llama, and Mistral) to reason in medicinal chemistry, biology, and clinical development with the precision required in modern pharma R&D.","length":517,"tagName":"p"},{"type":"text","content":"Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine invites pharma and biotech companies, AI labs, and cloud providers to "bring your AI model to Science MMAI Gym" and explore CSI, BSI, and PSI memberships tailored to their R&D pipelines.","length":265,"tagName":"p"},{"type":"text","content":"Addressing the LLM Performance Gap in Drug Discovery","length":52,"tagName":"p"},{"type":"text","content":"Despite their general intelligence, flagship LLMs often fail or underperform on mission-critical drug discovery tasks, such as predicting complex pharmacokinetic (DMPK) and toxicity endpoints (e.g., hERG, DILI risk, LD50). Insilico's benchmarks show that without specialized training, g...